drugset
drugset / Trial / NCT02558413

Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers

NCT02558413 ↗

Phase 1 Completed 60 enrolled Biota Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a placebo-controlled, double-blind, randomized, single dose escalation Phase 1 clinical trial to determine the safety and tolerability of BTA-C585 administered orally to healthy subjects.

Timeline

Start
2015-08
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator BTA-C585 Unknown 50 mg Oral
Comparator BTA-C585 Unknown 800 mg Oral

Indications

No indication recorded.